Oncology

Latest News

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

New Developments Warrant Rethinking HCC Transplant Criteria

By Jared Kaltwasser

April 29th 2025

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Women with fatigue | Image credit: Adobe Stock

Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

By Mary Caffrey

April 29th 2025

senior scientist | Image credit: Ohio State University

Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

By Mary Caffrey

April 28th 2025

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

January 31st 2018

CAR T-Cell Therapy Named ASCO's Advance of the Year

Jaime Rosenberg

Chimeric antigen receptor (CAR) T-cell therapy has been named the Advance of the Year in ASCO’s Clinical Cancer Advances 2018. According to the annual report, CAR T-cell therapy is “poised to transform the outlook for children and adults with certain otherwise incurable cancers."

January 30th 2018

Analysis Shows Majority of Hospitals Will See Payment Increases Despite 340B Payment Cuts

Jaime Rosenberg

As a result of the Medicare Outpatient Prospective Payment System rule that took effect on January 1, 85% of 340B hospitals will see net payment increases in 2018. Rural hospitals will reap the largest benefits, according to an analysis conducted by Avalere and commissioned by Community Oncology Alliance.

January 30th 2018

Nat Turner: Data Can Disrupt Clinical Research and Improve Patient Care

Nat Turner, co-founder and CEO of Flatiron Health, explains how data can be used for finding potential patients to be included in clinical trials.

January 30th 2018

Scientists Develop Tool to Analyze Links Between Lifestyle Choices and Certain Cancers

Kaitlynn Ely

A team of 20 scientists in the fields of informatics, statistics, epidemiology, systematic reviews, cancer biology, and nutrition have developed a tool that will assess the links in published human studies between lifestyle factors and cancer.

January 30th 2018

Using Health IT to Increase Medication Adherence and Enhance Precision Medicine

Jaime Rosenberg

As health information technology (IT) tools are continually being introduced into the healthcare sphere, organizations are utilizing these tools to optimize care coordination, patient experience, and patient outcomes. Today, 2 organizations join us; 1 uses a 2-way text messaging platform to support patients and increase medication adherence, and the other is teaming up with a pharmaceutical company to develop health IT solutions in order to enhance precision medicine in oncology.

January 29th 2018

Oncologists Overcome Hurdles to Deliver Cancer Care in Puerto Rico

Allison Inserro

Even though much more remains to be done on an island where half of its US residents still lack power, the situation is improving for cancer patients in Puerto Rico, doctors and organizations said recently in interviews with The American Journal of Managed Care®. In Puerto Rico, more than 75% of the cancer care is delivered in the community, not hospitals.

January 29th 2018

Dr Mark Fendrick: How Expensive Therapies Fit Into VBID for Oncology

When a drug becomes first-line, I would like to think that as a clinician I would have access to that, but most importantly that my patients would not have to have a bake sale or take out a second mortgage on their homes to get therapies that are designed specifically for them, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.

January 28th 2018

ASCO Provides CMS Recommendations on Revisions to Part D

Kaitlynn Ely

The American Society of Clinical Oncology (ASCO) recommends that CMS guard cancer patients from high out-of-pocket costs that will impede patient access to life-extending cancer drugs, according to the society’s comments regarding proposed financial revisions to the Medicare Prescription Drug Benefit Program (Part D).

January 27th 2018

Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer

Laura Joszt, MA

Every year, central lines are associated with causing blood infections in an estimated 400,000 patients with cancer. However, new research has found that changes in the microbiome may be responsible for some or many of the infections usually attributed to central lines.

January 27th 2018

Bo Gamble Explains How COA Helps Practices Prepare for OCM

Bo Gamble, director of Strategic Practice Initiatives at the Community Oncology Alliance (COA), explains how COA plays a role in supporting practices in preparing for Oncology Care Model.

January 26th 2018

Via Oncology Acquisition Positions Pathway Provider for Growth

Mary Caffrey

Via Pathways covers more than 2000 different patient representations in cancer care.

January 26th 2018

Study Notes Racial Differences in Risk of Recurrence Among Patients With Breast Cancer

Kaitlynn Ely

Non-Hispanic black women diagnosed with HER2-negative, lymph node-negative breast cancer who had recurrence score testing had higher estimated risks of distant recurrence than their non-Hispanic white counterparts.

January 25th 2018

High Cost Sharing Associated With Reduced Access to Targeted Therapies for Patients With mRCC

Jaime Rosenberg

High cost sharing is associated with reduced and/or delayed access to targeted therapies under Medicare Part D for patients with metastatic renal cell carcinoma, suggesting that financial barriers play a significant role in treatment decisions, according to a study published in Cancer Medicine.

January 24th 2018

Patients Prefer End-of-Life Care in Their Location of Choice

Kaitlynn Ely

Patients diagnosed with cancer want their doctors to ask them their desire location for end-of-life (EOL) care, according to a recent study published in the Journal of the National Comprehensive Cancer Network.

January 24th 2018

Dr Peter Aran on What Oncologists Implementing OCM Can Learn From Existing Models

Over the next years, these spheres (ACOs, primary care, and oncology) that are going on in CMMI need to be coalesced together so that when we have learning collaboratives, not only do we have learning collaboratives within each of these spheres, but we learn from each other in these similar projects, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma.

$Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM$

January 22nd 2018

Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM

Laura Joszt, MA

The FDA has approved a supplemental New Drug Application to add new overall survival (OS) data for carfilzomib (Kyprolis). The label will now show that carfilzomib and dexamethasone reduced the risk of death by 21% and increased OS by 7.6 months compared with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).

January 22nd 2018

The Fallacy of Estimating OCM Target Prices

Darcie Hurteau

Estimating episodic target prices for each patient in the Oncology Care Model (OCM) can be challenging and time consuming. Applying that time to quality-focused care management tactics, based on observed utilization and patient outcomes, may wind up being more valuable, and help to reduce unnecessary spending.

January 20th 2018

Treating Patients With Melanoma With Targeted Therapies Before Surgery Can Delay Relapse

Samantha DiGrande

Researchers at The University of Texas MD Anderson Cancer Center recently reported in Lancet Oncology that a pair of targeted therapies given before and after surgery for melanoma produced a 6-fold increase in time to progression of the disease, compared with standard-of-care surgery for patients with stage 3 melanoma.

January 20th 2018

Podcast: This Week in Managed Care—Kentucky's Medicaid Work Requirement and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

January 20th 2018

Dr Roger Brito Discusses Implementing Alternative Payment Models and Its Challenges

Aetna is focusing on the healthcare triangle (patients, providers, and payers) and connecting those lines, said Roger Brito, DO, national director for oncology, Aetna.

January 19th 2018

This Week in Managed Care: January 19, 2018

This week in managed care, the top stories included the announcement that Kentucky is the first state approved to require patients work to receive Medicaid benefits; FDA Commissioner Scott Gottlieb, MD, reveals a new program to improve clinical trial transparency; research finds the worst cases of attention-deficit/hyperactivity disorder could lower life expectancy.

January 19th 2018

Risk-Targeted Lung Cancer Screening Shows Modest Benefits

Samantha DiGrande

Although risk targeting may improve screening efficiency in terms of early lung cancer mortality per person screened, the gains in efficiency are modest in terms of life-years, quality-adjusted life-years, and cost-effectiveness, according to a study recently published in Annals of Internal Medicine.

January 19th 2018

Terrill Jordan Discusses the Process of Customizing an EMR to Adapt to OCM

In order to adapt to the Oncology Care Model (OCM), Regional Cancer Care Associates had to undergo the process of adjusting and customizing its electronic medical records, explained CEO Terrill Jordan.

January 19th 2018

Horizon, RCCA Launch Pilot to Close Care Gaps Between Cancer Treatments

Mary Caffrey

New Jersey's largest payer will track a host of measures, including some that will evaluate the quality of end-of-life care.

January 18th 2018

Dr Mark Fendrick: Setting Cost-Sharing Based on Value, Not Price, in Cancer Care

We should try to remove barriers that are not only in place, but getting higher for clinicians and patients to get evidence-based care, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.

January 18th 2018

Electronic Health Record Problem Lists: Accurate Enough for Risk Adjustment?

Timothy J. Daskivich, MD, MSHPM Garen Abedi, MD, MS Sherrie H. Kaplan, PhD, MPH Douglas Skarecky, BS Thomas Ahlering, MD Brennan Spiegel, MD, MSHS Mark S. Litwin, MD, MPH Sheldon Greenfield, MD

Electronic health record (EHR)-based comorbidity assessment had low sensitivity for identifying major comorbidities and poorly predicted survival. EHR-based comorbidity data require validation prior to application to risk adjustment.

January 18th 2018

Study Finds Protein Markers May Better Predict Drug Response in Patients With AML Than Genetic Mutations

AJMC Staff

A study finds that protein markers may be a better predictor of drug response than genetic mutation are in patients with acute myeloid leukemia (AML). As a result, some patients who could benefit from treatment may not be eligible under current approval specifications.

January 16th 2018

Poor Baseline LIPI Associated With Worse Outcomes for ICI Treatment in Patients With NSCLC

Jaime Rosenberg

Poor baseline Lung Immune Prognistic Index (combining derived neutrophils ratio greater than 3 and lactate dehydrogenase greater than upper limit of normal), or LIPI, was associated with worse outcomes for immune checkpoint inhibitor (ICI) treatment in patients with non-small cell lung cancer (NSCLC), but not with results of chemotherapy, according to a study in JAMA Oncology.

January 16th 2018

What We're Reading: Language of Medicine; Uninsured Number Grows; 3D Mammograms

AJMC Staff

The language used by doctors contributes to why patients don't understand what they are told; the number of American adults without health insurance grew 1.3 percentage points from the end of 2016 to the end of 2017; women are increasingly faced with the decision between 2D and 3D mammograms.

January 14th 2018

Julie Wolfson: Supporting AYAs Before and After Treatment

The challenges that adolescents and young adults face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.

...

56 57 58 59 60 61 62 63 64

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions